William H. Sharfman

Bloomberg (United States) — United States

Medicine · Health Sciences

46h-index29.7kcitations129works22.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(71), CAR-T cell therapy research(43), Immunotherapy and Immune Responses(37), Melanoma and MAPK Pathways(17), Polyomavirus and related diseases(13)

Publications128 total

Primary resistance to ICI-based regimens is associated with early longitudinal changes in the fecal microbiome and loss of microbial stability
2025Open Access
Nivolumab With or Without Ipilimumab in Patients With Recurrent or Metastatic Merkel Cell Carcinoma: A Nonrandomized, Open-Label, International, Multicenter Phase I/II Study
Journal of Clinical Oncology·2025· 15 citedOpen Access
695 Phase 2 study of nivolumab and ipilimumab in combination with sirolimus and prednisone in kidney transplant recipients with selected unresectable or metastatic cutaneous cancers
Regular and Young Investigator Award Abstracts·2024Open Access
Immune-related encephalitis after immune checkpoint inhibitor therapy
The Oncologist·2024· 23 citedOpen Access
Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1–2, open-label, multicohort trial
The Lancet Oncology·2024· 48 cited
Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumors
Journal for ImmunoTherapy of Cancer·2024· 23 citedOpen Access
Nivolumab + Tacrolimus + Prednisone ± Ipilimumab for Kidney Transplant Recipients With Advanced Cutaneous Cancers
Journal of Clinical Oncology·2024· 46 citedOpen Access
CTIM-03. LONG TERM FOLLOW-UP OF A PROSPECTIVE SAFETY AND TOXICITY STUDY OF IMMUNE CHECKPOINT INHIBITOR THERAPY INITIATED 8 DAYS PRIOR TO RADIOSURGERY FOR MELANOMA BRAIN OR SPINE METASTASIS
Neuro-Oncology·2023· 1 citedOpen Access
Non-comparative, open-label, international, multicenter phase I/II study of nivolumab (NIVO) ± ipilimumab (IPI) in patients (pts) with recurrent/metastatic merkel cell carcinoma (MCC) (CheckMate 358).
Journal of Clinical Oncology·2023· 13 cited
Supplementary Figure Legends from Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non–Small Cell Lung Cancer
2023Open Access
Supplementary Figures S1 - S16 from Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non–Small Cell Lung Cancer
2023Open Access
Data from Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non–Small Cell Lung Cancer
2023Open Access
Supplementary Figures S1 - S16 from Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non–Small Cell Lung Cancer
2023Open Access
Supplementary Tables S1 - S18 from Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non–Small Cell Lung Cancer
2023Open Access
Supplementary Tables S1 - S18 from Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non–Small Cell Lung Cancer
2023Open Access
Supplementary Figure Legends from Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non–Small Cell Lung Cancer
2023Open Access
Data from Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non–Small Cell Lung Cancer
2023Open Access
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
Journal of Clinical Oncology·2023· 229 cited
Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
Journal of Clinical Oncology·2023· 218 cited
711 Interim results of a phase 2 study of nivolumab and relatlimab in advanced mismatch repair deficient (dMMR) cancers resistant to prior PD-(L)1 inhibition
Regular and Young Investigator Award Abstracts·2022· 3 citedOpen Access
page 1 of 7Next →

Frequent Co-authors

Suzanne L. Topalian(21), Evan J. Lipson(18), Janis M. Taube(17), F. Stephen Hodi(15), Drew M. Pardoll(12), Julie R. Brahmer(11), Jeffrey A. Sosman(11), Mario Sznol(10), David F. McDermott(9), John D. Powderly(9), Michael B. Atkins(9), Shailender Bhatia(9), Harriet M. Kluger(9), Richard D. Carvajal(8), Donald P. Lawrence(8), Walter J. Urba(7), Igor Puzanov(7), David C. Smith(6), Philip D. Leming(6), Robert A. Anders(6)